Clinical Trial Update: Follow-up Study 16-20 Years After Primary Vaccination Against Hepatitis B of Newborns From HBeAg+ & HBsAg+ Mothers [Phase 4]

View source ↗

Summary

This Phase 4 follow-up study assesses long-term durability of protection 16-20 years after newborn vaccination against Hepatitis B in children born to HBeAg+ an…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• Engerix-B (hepatitis B vaccine)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Hepatitis B | Phase 4 | Status: COMPLETED | Results posted: 2009-05-01